Major Indexes Narrowly Lower As Actavis Rallies
at Investor's Business Daily - Mon Jun 23, 12:29PM CDT
Despite better-than-expected economic data, the major averages were still trading flat to slightly lower in early-afternoon trading. The Nasdaq was flat, while the S&P 500 edged down 0.1% and the Dow industrials eased 0.2%. Volume was tracking well...
3 Stocks Driving The Health Care Sector Higher
at The Street - Mon Jun 23, 12:09PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Unusual Social Activity Today Around Actavis (ACT)
at The Street - Mon Jun 23, 10:41AM CDT
Trade-Ideas LLC identified Actavis (ACT) as an unusual social activity candidate
Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
Business Wire - Mon Jun 23, 7:30AM CDT
--- Proven Development Track Record in Key Therapeutic Categories including Women's Health, Psychiatric and Cardiovascular -
Settlements, Statements, FDA Submissions and Approvals - Analyst Notes on Valeant, Pfizer, Actavis, Allergan and Teva
PR Newswire - Fri Jun 20, 5:20AM CDT
Today, Analysts Review released its analysts' notes regarding Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT), Allergan, Inc. (NYSE: AGN) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3940-100free.
Teva's Nuvigil Patent Infringement Lawsuits Resolved - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 3:45PM CDT
Teva (TEVA) settled its patent infringement lawsuits for Nuvigil with Sandoz, Actavis (ACT), Lupin and Apotex.
Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.
Actavis Confirms District Court Ruling In Generic Exelon® Patch Patent Suit
PR Newswire - Thu Jun 19, 7:30AM CDT
Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the District of Delaware has found certain claims of United States Patent Nos. 6,335,031 and 6,316,023 valid and infringed by Actavis' generic version of Novartis' Exelon® Patch (rivastigmine transdermal system). Actavis is reviewing the court's decision and will evaluate all available options, including an appeal.
Nasdaq, S&P 500 Rally To New Highs After Fed Meeting
at Investor's Business Daily - Wed Jun 18, 3:20PM CDT
The major averages rallied after the Fed said it would keep interest rates near zero and trimmed monthly bond purchases by $10 billion, to $35 billion. The Fed lowered its 2014 economic growth forecast to between 2.1% and 2.3%, from 2.9%, but said...
Stocks Open Mixed In Firm Trade; Adobe, FedEx, Air Products Jump
at Investor's Business Daily - Wed Jun 18, 9:33AM CDT
Stocks churned out a mixed open Wednesday as earnings reports fueled some significant early moves. The Nasdaq slipped 0.2%. The Dow Jones industrial average was down 0.1%. The S&P 500 hung on to a fractional gain. Investor attention on the stock...
Research and Markets: Global IV Iron Drugs Market Report: 2014 Edition
Business Wire - Wed Jun 18, 8:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qdwk3z/global_iv_iron) has announced the addition of the "Global IV Iron Drugs Market Report: 2014 Edition" report to their offering.
Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
at Investor's Business Daily - Wed Jun 18, 7:02AM CDT
With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm -- or face, in the case of Botox maker Allergan (AGN). But not all offers have been...
2014 Report on the International Human Reproductive Technologies Market - Forecast to 2019
M2 - Wed Jun 18, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d66cdt/human) has announced the addition of the "2014 Report on the International Human Reproductive Technologies Market - Forecast to 2019" report to their offering. This report covers the market analysis for various drugs, devices and treatment technologies used in assistance and to control human reproduction. The stakeholders for this study include manufacturers and providers of contraceptive technologies and infertility solutions. The market overview section of the report demonstrates the market dynamics and trends such as the drivers, restraints and opportunities that influence the current nature and future status of this field. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global human reproductive technologies market. The global human reproductive technologies market is categorized on the basis of various infertility treatments and contraceptive technologies. The infertility technologies market is analyzed in this report with respect to drugs as well as types of treatment procedures. With respect to drugs, the report includes leading brands (by sales) from three major classes, namely, gonadotropins, androgens and erectile dysfunction. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Human Reproduction Technologies Market, by Infertility Treatment Chapter 5 Global Human Reproductive Technologies Market, by Contraceptive Technologies Chapter 6 Global Human Reproductive Technologies Market Revenue, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc. - Actavis, Inc. - Bayer AG - Church & Dwight, Co. Inc. - Cook Medical, Inc. - Ferring International Center S.A. - Johnson & Johnson - Merck & Co., Inc. - Merck Serono - Pfizer, Inc. - Reckitt Benckiser Group plc - Teva Pharmaceutical Industries Ltd. - Warner Chilcott plc For more information visit http://www.researchandmarkets.com/research/d66cdt/human
Global IV Iron Drugs Market Report: 2014 Edition
M2 - Wed Jun 18, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/knfh2j/global_iv_iron) has announced the addition of the "Global IV Iron Drugs Market Report: 2014 Edition" report to their offering. The report analyzes the global iron products industry along with an extensive coverage of global and the US IV iron market. The global IV iron market witnesses intense competition with numerous top notch players; such as Galenica Pharmaceuticals, Actavis Inc, AMAG Pharmaceuticals; operating in the marketplace along with small budding players. As a part of analysis of fierce competition prevailing in the industry, product contention has been presented in the report. The company profiles of leading aforementioned players in the market are also incorporated in the report. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron. The key factors driving growth of the global IV iron industry include escalating number of dialysis and hypertension cases, ameliorating economic conditions, increasing global healthcare expenditures, and rising medicines expenditures. Some of the noteworthy trends and developments of this industry encompass novel product development, bundled payment systems and increasing penetration of genecology sector. However, the growth of this industrial sector is being hindered by stringent regulatory structures and adverse affects associated with the use of IV iron products. Key Topics Covered: 1. Iron in Human Body: An Overview 2. Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - AMAG Pharmaceuticals - Actavis Inc. - Galenica Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/kn...al_iv_iron
Actavis' shareholders approves planned acquisition of Forest for about USD25bn in cash and stock
M2 - Wed Jun 18, 3:52AM CDT
Specialist pharmaceutical company Actavis (NYSE:ACT) stated on Tuesday that all proposals related to its planned acquisition of Forest Laboratories (NYSE:FRX) were approved by their respective shareholders at the recent shareholder meetings.
Actavis and Forest Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Forest
Business Wire - Tue Jun 17, 3:17PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that, at shareholder meetings held today, all proposals related to Actavis' planned acquisition of Forest were approved by both Actavis' and Forest's shareholders.
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors
Business Wire - Tue Jun 17, 7:01AM CDT
Cardax, Inc. ("Cardax"
Actavis Strives To Reduce Borrowing Costs
at Investor's Business Daily - Fri Jun 13, 5:48PM CDT
Generic, branded and biosimilar drugmaker Actavis (ACT) may be well-known among investors as a company that has used large acquisitions as one method to boost its earnings and sales sharply. Yet less attention perhaps has been paid to its savvy...